Skip to main content
Top

27-12-2016 | Neuroendocrine tumors | Book chapter | Article

1. Classification of Neuroendocrine Neoplasms

Authors: Frediano Inzani, Guido Rindi

Publisher: Springer International Publishing

Abstract

Neuroendocrine neoplasms (NENs) are made by transformed cells producing hormone/mediators and characterized by the shared expression of some neural-specific antigens. NENs may arise in nerve structures, endocrine organs, and in the diffuse neuroendocrine system at various organs and apparata. The rarity, complexity, and diversity of NENs impaired the development of shared definition and classification. Organ-specific classifications have been historically developed and are in use and formalized under the World Health Organization authority. Common classification themes however do exist including common morphology features for most well-differentiated low-grade tumors and for high-grade, poorly differentiated carcinomas, though with diverse prevalence at different anatomical sites. Common features and specific classifications schemes are briefly discussed here.
Literature
1.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. 3rd ed. World Health Organization classification of tumours. Lyon: IARC Press; 2004.
2.
Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of tumours of head and neck. 3rd ed. World Health Organization classification of tumours. Lyon: IARC Press; 2005.
3.
LeBoit PE, Burg G, Weedon D, Sarasain A. Pathology and genetics of skin tumours. 3rd ed. World Health Organization classification of tumours. Lyon: IARC Press; 2006.
4.
Bosman F, Carneiro F, Hruban RH, Theise ND. Pathology and genetics of tumours of the digestive system. 4th ed. World Health Organization classification of tumours. Lyon: IARC Press; 2010.
5.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. Pathology and genetics of tumours of the breast. 4th ed. World Health Organization Classification of tumours. Lyon: IARC Press; 2012.
6.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. Pathology and genetics of tumours of female reproductive organs. 4th ed. World Health Organization classification of tumours. Lyon: IARC Press; 2014.
7.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Pathology and genetics of tumours of the lung, pleura, thymus and heart. 4th ed. World Health Organization classification of tumours. Lyon: IARC Press; 2015.
8.
Moch H, Humphrey PA, Ulbright TM, Reuter VE. Pathology and genetics of tumours of the urinary system and male genital organs. 4th ed. World Health Organization classification of tumours. Lyon: IARC Press; 2016.
11.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72. doi:10.​1016/​S1470-2045(07)70410-2.CrossRefPubMed
12.
Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumours. J Natl Cancer Inst. 2008;100(18):1282–9. doi:10.​1093/​jnci/​djn275.
13.
Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumours: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97. doi:10.​1002/​cncr.​29099.
14.
Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2012;8(1):54–64. doi:10.​1038/​nrendo.​2011.​120.CrossRef
15.
La Rosa S, Pariani D, Calandra C, Marando A, Sessa F, Cortese F, et al. Ectopic duodenal insulinoma: a very rare and challenging tumour type. Description of a case and review of the literature. Endocr Pathol. 2013;24(4):213–9. doi:10.​1007/​s12022-013-9262-y.
16.
Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104(10):764–77. doi:10.​1093/​jnci/​djs208.CrossRefPubMed
17.
Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, et al. Grading the neuroendocrine tumours of the lung: an evidence-based proposal. Endocr Relat Cancer. 2014;21(1):1–16. doi:10.​1530/​ERC-13-0246.
18.
Scheithauer BW, Horvath E, Abel TW, Robital Y, Park SH, Osamura RY, et al. Pituitary blastoma: a unique embryonal tumour. Pituitary. 2012;15(3):365–73. doi:10.​1007/​s11102-011-0328-x.
19.
Kodama T, Okamoto T, Fujimoto Y, Obara T, Ito Y, Aiba M, et al. C cell adenoma of the thyroid: a rare but distinct clinical entity. Surgery. 1988;104(6):997–1003.PubMed
20.
Eusebi V, Damiani S, Riva C, Lloyd RV, Capella C. Calcitonin free oat-cell carcinoma of the thyroid gland. Virchows Arch A Pathol Anat Histopathol. 1990;417(3):267–71.CrossRefPubMed
21.
Rindi G, Arnold R, Capella C, Klimstra DS, Klöppel G, Komminoth P, et al. Nomenclature and classification of digestive neuroendocrine tumours. In: Bosman F, Carneiro F, editors. World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010. p. 10–2.
22.
Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumours: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401. doi:10.​1007/​s00428-006-0250-1.
23.
Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumours: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–62. doi:10.​1007/​s00428-007-0452-1.
24.
Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649–57. doi:10.​1530/​ERC-13-0027.CrossRefPubMed
25.
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2013;24:152–60. doi:10.​1093/​annonc/​mds276.CrossRef
26.
Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, et al. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol. 2015;50(5):564–72. doi:10.​1007/​s00535-014-0987-2.CrossRefPubMed
27.
Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumour category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90. doi:10.​1097/​PAS.​0000000000000408​.
28.
Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64. doi:10.​1530/​ERC-15-0119.CrossRefPubMed
29.
Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756–67. doi:10.​1097/​PAS.​0000000000000208​.CrossRefPubMedPubMedCentral